A dose-escalation study of bi-daily once weekly oral docetaxel either as ModraDoc001 or ModraDoc006 combined with ritonavir

INTRODUCTION: Two solid dispersions of docetaxel (denoted ModraDoc001 capsule and ModraDoc006 tablet (both 10 mg)) were co-administered with 100 mg ritonavir (/r) and investigated in a bi-daily once weekly (BIDW) schedule. Safety, maximum tolerated dose (MTD), pharmacokinetics (PK) and preliminary activity were explored. METHODS: Adult patients with metastatic solid tumours were included in two dose-escalation arms. PK sampling was performed during the first week and the second or third week. Safety was evaluated using US National Cancer Institute's Common Terminology Criteria for Adverse Even... Mehr ...

Verfasser: de Weger, Vincent A
Stuurman, Frederik E
Hendrikx, Jeroen J M A
Moes, Johannes J
Sawicki, Emilia
Huitema, Alwin D R
Nuijen, Bastiaan
Thijssen, Bas
Rosing, Hilde
Keessen, Marianne
Mergui-Roelvink, Marja
Beijnen, Jos H
Schellens, Jan H M
Marchetti, Serena
Dokumenttyp: Artikel
Erscheinungsdatum: 2017
Schlagwörter: Administration / Oral / Adult / Aged / Antineoplastic Combined Chemotherapy Protocols / Area Under Curve / Capsules / Drug Administration Schedule / Drug Compounding / Drug Dosage Calculations / Female / Half-Life / Humans / Male / Maximum Tolerated Dose / Metabolic Clearance Rate / Middle Aged / Neoplasms / Netherlands / Ritonavir / Tablets / Taxoids / Treatment Outcome / Clinical Trial / Phase I / Comparative Study / Taverne
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29202013
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://dspace.library.uu.nl/handle/1874/361844